Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorMontreal Heart Institute
About this trial
In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.
Eligibility criteria
Qualifiers
Age ≥18 years;
Hospitalized for type 1 MI, according to the 4th Universal Definition of MI;
Coronary angiogram performed;
Planned for medical management alone, without revascularization;
Disqualifiers
Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI;
Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel;
Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.);
Confirmed or suspected spontaneous coronary artery dissection;
Trial design
Treatments tested in this trial
- Ticagrelor + placebo
- Ticagrelor + aspirin
Treatment groups
2,570 Participants
are divided into 2 treatment groupsSponsors and collaborators
Montreal Heart Institute
Lead sponsor
Université de Montréal
Sponsor institution
Source ClinicalTrials.gov